Jack Meng-Fen Su, MD
- Cancer and Blood Disorders
Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Hyundai Pediatric Cancer Research Scholar
Departments:
Office locations:
Texas Medical Center
6701 Fannin Street
Houston, TX 77030
Get to know Jack Meng-Fen Su, MD
Personal Statement
Dr. Jack Su's clinical interest is in neuro-oncology.
Board Certifications
American Board of Pediatrics
American Board of Pediatrics - Pediatric Hematology-Oncology
Clinical Interests
Dr. Jack Su's clinical interest is in neuro-oncology.
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Baylor College of Medicine | Masters | Master of Science, Clinical Investigation | 2007 |
| Baylor College of Medicine | Fellowship | Pediatric Oncology Clinical Research | 2006 |
| Baylor College of Medicine | Fellowship | Pediatric Hematology-Oncology | 2001 |
| University of California School of Medicine - San Francisco | Residency | Pediatrics | 1997 |
| University of California, San Francisco | Medical School | Doctor of Medicine | 1990 |
| Stanford University | Bachelors | Bachelor of Science, Chemistry | 1986 |
Organizations
| Organization Name | Role |
|---|---|
| Pediatric Brain Tumor Consortium (PBTC) | Member |
| Society of Neuro-Oncology (SNO) | Member |
| American Association of Cancer Research (AACR) | Member |
Board Certification
American Board of Pediatrics
American Board of Pediatrics - Pediatric Hematology-Oncology
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Dr. Jack Su's research interest is in translational oncology and developing novel agents for treating pediatric CNS tumors. Dr. Su is currently conducting a Children's Oncology Group (COG) phase I study of valproic acid in children with recurrent solid tumors, including brain tumors. He is also developing clinical trials of additional histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), and a poly(ADP-ribose) polymerase (PARP) inhibitor for pediatric CNS tumors.
Dr. Su is conducting pre-clinical studies of HDAC inhibitors, PARP inhibitors, and DNA methylation inhibitors for future clinical trials in pediatric CNS tumors.His research interests are in translational oncology and developing novel agents for treating pediatric CNS tumors.
